Literature DB >> 19433659

Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.

Aaron Boster1, Stephanie Hreha, Joseph R Berger, Fen Bao, Ramya Penmesta, Alexandros Tselis, Christina Endress, Imad Zak, Jai Perumal, Christina Caon, Jose Vazquez, Kenneth L Tyler, Michael K Racke, Scott Millis, Omar Khan.   

Abstract

OBJECTIVE: To identify clinical and magnetic resonance imaging (MRI) features that distinguish progressive multifocal leukoencephalopathy (PML) from relapsing-remitting multiple sclerosis (RRMS).
DESIGN: Retrospective medical record review.
SETTING: Two urban teaching hospitals in Detroit, Michigan. Patients Forty-five confirmed PML cases and 100 patients with RRMS. MAIN OUTCOME MEASURES: Clinical and MRI features distinguishing PML from RRMS.
RESULTS: Overall, monosymptomatic presentations were more common in multiple sclerosis (MS) than PML (85% vs 47%; P < .01). However, patients with PML presented more often with hemiparesis (24% vs 5%; P = .001) and altered mentation (19% vs 0%; P < .0001), whereas brainstem (2% vs 18%; P = .007) presentations were more common in patients with RRMS. Spinal cord and optic neuritis presentations were seen in 18% and 33% of patients with RRMS, respectively, but not in patients with PML (m < .0001). Brain MRI scans, available in 35 (78%) PML cases, revealed 7 lesion types. Large, confluent T2-weighted lesions (74% vs 2%; P < .0001) and deep gray matter lesions (31% vs 7%; P < .001) were more frequent in patients with PML than patients with RRMS. Crescentic cerebellar lesions (23% vs 0%; P < .001) were seen only in patients with PML. Gadolinium-enhancing (23%), transcallosal (9%), and periventricular (9%) lesions were noted in patients with PML. Brain magnetization transfer ratio (MTR) was low in both PML and MS lesions. However, normal-appearing brain tissue MTR in PML was higher than normal-appearing brain tissue MTR in RRMS (44.15% vs 41.04%; P = .002), suggesting that PML may be relatively more focal than MS.
CONCLUSIONS: There appear to be differences between the clinical and MRI characteristics of PML and RRMS, which may help distinguish new MS activity from PML. Magnetization transfer ratio studies may provide additional clues in improving early detection of PML in patients with preexisting MS and warrant further investigation.

Entities:  

Mesh:

Year:  2009        PMID: 19433659     DOI: 10.1001/archneurol.2009.31

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  12 in total

Review 1.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 2.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 3.  Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy.

Authors:  Martyn K White; Ilker K Sariyer; Jennifer Gordon; Serena Delbue; Valeria Pietropaolo; Joseph R Berger; Kamel Khalili
Journal:  Rev Med Virol       Date:  2015-12-14       Impact factor: 6.989

Review 4.  Managing MS in a changing treatment landscape.

Authors:  Martin Duddy; Aiden Haghikia; Eleonora Cocco; Christian Eggers; Jelena Drulovic; Olga Carmona; Helene Zéphir; Ralf Gold
Journal:  J Neurol       Date:  2011-03-25       Impact factor: 4.849

5.  Clinical Reasoning: An 83-year-old woman with progressive hemiataxia, tremor, and infratentorial lesions.

Authors:  Karen Aquino; Igor J Koralnik; David Silvers
Journal:  Neurology       Date:  2011-07-12       Impact factor: 9.910

Review 6.  Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Authors:  Mark S Igra; David Paling; Mike P Wattjes; Daniel J A Connolly; Nigel Hoggard
Journal:  Br J Radiol       Date:  2017-04-26       Impact factor: 3.039

7.  Progressive multifocal leukoencephalopathy in a patient with systemic sclerosis treated with methotrexate: A case report and literature review.

Authors:  Theodora Simopoulou; Vana Tsimourtou; Christina Katsiari; Marianna Vlychou; Dimitrios P Bogdanos; Lazaros I Sakkas
Journal:  J Scleroderma Relat Disord       Date:  2020-06-18

Review 8.  Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.

Authors:  Shitiz Sriwastava; Durgesh Chaudhary; Samiksha Srivastava; Katherine Beard; Xue Bai; Sijin Wen; Syed Hassan Khalid; Robert P Lisak
Journal:  J Neurol       Date:  2021-11-20       Impact factor: 4.849

9.  Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.

Authors:  Aiden Haghikia; Moritz Perrech; Bartosz Pula; Sabrina Ruhrmann; Anja Potthoff; Norbert H Brockmeyer; Susan Goelz; Heinz Wiendl; Hans Lindå; Tjalf Ziemssen; Sergio E Baranzini; Tor-Björn Käll; Dietmar Bengel; Tomas Olsson; Ralf Gold; Andrew Chan
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

10.  Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.

Authors:  Alessandra Sottini; Ruggero Capra; Cinzia Zanotti; Marco Chiarini; Federico Serana; Doris Ricotta; Luigi Caimi; Luisa Imberti
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.